about
Cholinesterase inhibitors for rarer dementias associated with neurological conditionsCholinesterase inhibitors for neurological conditions associated with rarer dementiasCholinesterase inhibitors for rarer dementiasTestosterone supplementation for mild cognitive impairment and dementiaAntibiotics and antivirals for dementia and mild cognitive impairmentThiazolidinediones for dementia and mild cognitive impairmentGenetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathwaysSelective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's diseaseGenomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease.Does ionizing radiation influence Alzheimer's disease risk?Pharmacogenomics and treatment for dementia induced by Alzheimer's disease.Pharmacogenomics and therapeutic strategies for dementia.Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease.Genomics and pharmacogenomics of dementia.Epigenetic drug discovery for Alzheimer's disease.Genomic medicine and risk prediction across the disease spectrum.Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Republished: the role of amyloid β in the pathogenesis of Alzheimer's disease.Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease.Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants.
P2860
Q24187428-891441D2-D457-4EAC-AC6F-7840C260E2A3Q24201472-B493D2AE-3B4A-40A4-ABFD-5B9900C7716DQ24235750-7C8FE1D3-6BC2-41CB-8DAD-668151A4ECB9Q24240719-8A9944B9-35EA-4554-8CE3-BFB85E55C3EFQ24240866-4CBD0738-C912-4FBF-A9F6-95E5E4DA324EQ24242116-67301860-BC11-419B-BA3B-AF437191F433Q24629875-143EE3F8-21F3-4AE1-9638-EFC5FAD03F3EQ33496258-8C880745-8A1F-4E10-9248-A8B4188D687DQ35082774-2BA42A56-C7C7-4D4E-B24E-529087CDB12CQ35852564-AD72A967-B040-4B47-8118-F61FFB37F008Q36195468-346BE4A3-631E-4128-8214-441CED7F02EBQ36355750-8FA56102-1EFB-4AAF-9B5A-AD374EF735A2Q37205951-560360B9-EC11-45DF-8C9F-931E30F420E8Q37592250-AE4703D8-72A3-45EF-8B3D-2C60DE4ED0BAQ37772498-1D47461D-83C2-457A-BE8D-BFDB61CBB462Q37780790-6F43568E-2E42-4433-B55B-366899EE08D7Q38225708-6A01E96E-EC24-4FD7-9664-F5A1CF7972AFQ38322338-9F117D49-953A-4B80-8C93-79882B26764CQ38860423-FD10B8EE-2A2D-4A17-B867-D05A1828C6C7Q46943581-EB9316F1-9212-4BA4-95A9-B6DF8BC429CBQ50636887-70040040-4CE9-4194-B16F-E4002538AB1BQ51847733-DE363371-ADE1-4DEC-8EC6-CC667E70578DQ53427766-F0896AE7-B208-4FF4-8283-9C44DC5E99B6Q55266735-39C96397-947B-40FD-93CD-2A8FFFA26E46
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenomics and therapeutic prospects in dementia.
@en
Pharmacogenomics and therapeutic prospects in dementia.
@nl
type
label
Pharmacogenomics and therapeutic prospects in dementia.
@en
Pharmacogenomics and therapeutic prospects in dementia.
@nl
prefLabel
Pharmacogenomics and therapeutic prospects in dementia.
@en
Pharmacogenomics and therapeutic prospects in dementia.
@nl
P2860
P1476
Pharmacogenomics and therapeutic prospects in dementia.
@en
P2860
P2888
P356
10.1007/S00406-007-1006-X
P478
258 Suppl 1
P577
2008-03-01T00:00:00Z